49Z Stock Chart & Stats
€1.79
-€0.02(-1.97%)
At close: 4:00 PM EDT
€1.79
-€0.02(-1.97%)
Day’s Range― - ―
52-Week Range€1.19 - €2.25
Previous CloseN/A
Volume0.00
Average Volume (3M)1.02K
Market Cap
€140.34M
Enterprise Value€1.20B
Total Cash (Recent Filing)€627.60M
Total Debt (Recent Filing)€266.40M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 11, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.89
Shares Outstanding69,074,900
10 Day Avg. Volume1,276
30 Day Avg. Volume1,018
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)€145.41M
Bulls Say, Bears Say
Bulls Say
Gross Margin And EBITDA ImprovementMaterial gross-margin expansion and a return to positive adjusted EBITDA indicate improved product mix, pricing, and operating discipline. If sustained, these changes can strengthen earnings quality, support reinvestment, and improve the scalability of BICO's life science tools platform.
Long-Term Scienion AgreementThe decade-long Scienion supply and license commitment adds contractual revenue visibility beyond ordinary equipment cycles. It also validates BICO's technology and commercial relationships, while creating a durable base for recurring activity and future customer expansion.
Strengthened Balance SheetThe move to net cash and substantial cash reserves improve financial flexibility compared with the prior net-debt position. A stronger balance sheet can help BICO fund product development, absorb operational volatility, and pursue organic or selective bolt-on opportunities.
Bears Say
Deeply Negative ProfitabilityBICO has not yet converted revenue into durable profits, with deeply negative net and operating margins despite improved gross margin. Continued losses can consume capital, limit internally funded growth, and increase the risk of dilution or renewed leverage over the next several quarters.
Weak And Volatile Cash GenerationNegative free cash flow and only modest underlying operating cash generation reduce BICO's ability to self-fund operations and investment. Working-capital swings add volatility, making liquidity management and the timing of cash conversion important even after the balance-sheet improvement.
Project Execution And Demand HeadwindsExecution problems in the U.S. project business can delay revenue recognition and increase delivery complexity, while soft academic demand and longer automation sales cycles weigh on order conversion. Together, these factors make growth and margins less predictable than recurring consumables trends.
BICO Group AB Class B News
49Z FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was €1.19 and its highest was €2.25 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is €140.34M.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Nov 11, 2026 which is in 37 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Aug 19, 2026. The company reported -€0.044 earnings per share for the quarter, beating the consensus estimate of -€0.062 by €0.018.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.01.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -€0.044 in its last earnings report, beating expectations of -€0.062. Following the earnings report the stock price went up 19.372%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in DE:49Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
49Z Company Deck
49Z Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call combined meaningful operational and financial improvements (strong product launches, a large long-term license/supply agreement, substantial gross margin expansion, improved adjusted EBITDA margin, reductions in operating expenses and a stronger balance sheet) with persistent operational and market headwinds (project execution issues in the U.S. project business, negative operating cash flow driven by working capital movements, soft North American/academic end markets and longer sales cycles for large automation projects). Progress on commercialization and profitability is clear, but execution risk in project-based automation and short-term cash-flow/working-capital pressure leave mixed near-term visibility.View all DE:49Z earnings summariesTechnical Analysis
Vitrolife AB
―
BONESUPPORT HOLDING AB
―
CellaVision AB
―
Xvivo Perfusion AB
―
OssDsign AB
―